Patients with inflammatory bowel disease (IBD) are at increased risk for pneumonia and if hospitalized, have a higher mortality. Based on the Centers for Disease Control (CDC) guidelines published in 2012, vaccination with both the pneumococcal polysaccharide vaccine (PPSV23) and the pneumococcal conjugate vaccine (PCV13) is recommended for IBD patients who are receiving immunosuppressive treatment (steroids, immunomodulators, and/or biologics). Previous studies have shown low pneumococcal vaccination rates among IBD patients, yet few have assessed which specific vaccines are recommended and administered.